drugset / Trial / NCT07241767
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Timeline
- Start
- 2025-11-12
- Primary completion
- 2027-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | FH-006 | Unknown | — | — |
| Subject | SHR-8068 | Monoclonal antibody | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |